Singapore markets open in 8 hours 31 minutes
  • Straits Times Index

    3,247.76
    -35.59 (-1.08%)
     
  • S&P 500

    4,336.16
    -73.97 (-1.68%)
     
  • Dow

    34,062.77
    -301.73 (-0.88%)
     
  • Nasdaq

    13,513.00
    -342.13 (-2.47%)
     
  • BTC-USD

    36,830.65
    +2,482.90 (+7.23%)
     
  • CMC Crypto 200

    837.87
    +17.28 (+2.11%)
     
  • FTSE 100

    7,360.26
    +63.11 (+0.86%)
     
  • Gold

    1,847.90
    +6.20 (+0.34%)
     
  • Crude Oil

    84.68
    +1.37 (+1.64%)
     
  • 10-Yr Bond

    1.7460
    +0.0110 (+0.63%)
     
  • Nikkei

    27,131.34
    -457.03 (-1.66%)
     
  • Hang Seng

    24,243.61
    -412.85 (-1.67%)
     
  • FTSE Bursa Malaysia

    1,508.91
    -12.95 (-0.85%)
     
  • Jakarta Composite Index

    6,568.17
    -86.99 (-1.31%)
     
  • PSE Index

    7,288.21
    +35.57 (+0.49%)
     

TheraVet: Commercial Launch of BIOCERA-VET® for Canine Osteosarcoma in Belgium, France and The Netherlands

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ALVET.PA
  • Start of commercialization, as planned, of BIOCERA-VET® Osteosarcoma, a game-changer in the palliative management of bone cancer in companion animals

  • Limb-sparing BIOCERA-VET® cementoplasty approach significantly relieves pain and improves quality of life of dogs with bone cancer

GOSSELIES, Wallonia, Belgium, December 09, 2021--(BUSINESS WIRE)--Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today the commercial launch of BIOCERA-VET® - Osteosarcoma in Belgium, France and The Netherlands.

Canine osteosarcoma is the most frequent and most aggressive dog primary bone cancer affecting more than 30.000 patients per year in Europe and in United-States. Currently, osteosarcoma management is mainly performed by amputation or limb-sparing surgeries associated with chemotherapy. Unfortunately these invasive approaches are not always the optimal option for the pets and the owners, looking for more palliative and qualitative alternatives such as BIOCERA-VET® - Osteosarcoma used in a minimally invasive surgical technique consisting in cementing the tumoral site with BIOCERA-VET®.

With this new step, TheraVet is pursuing, as planned, its commercial expansion strategy with the launch of the second product of its bone substitute product line, BIOCERA-VET® - Osteosarcoma, in Belgium, France and in The Netherlands.

Based on promising efficacy and safety results disclosed earlier this year, BIOCERA-VET®- Osteosarcoma represents a game-changer option in the management of canine osteosarcoma.

Enrico Bastianelli, Chief Executive Officer of TheraVet, concludes: "Based on solid clinical evidences, it can now be said that BIOCERA-VET® - Osteosarcoma will meet an important need in the palliative management of canine osteosarcoma by relieving pain and improving the quality of life of our beloved pets through a minimally invasive approach. We are therefore very happy to make it available."

About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris et Brussels, its head office is in Gosselies, Belgium, and it has a subsidiary in the US.

For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter.

For more information about BIOCERA-VET®- Osteosarcoma, visit www.bioceravet.be, www.bioceravet.fr and www.bioceravet.nl.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006112/en/

Contacts

TheraVet
Sabrina Ena
Chief Operating Officer
sabrina.ena@thera.vet
+32 (0)71 96 00 43

Julie Winand
Chief Corporate Officer
julie.winand@thera.vet

NewCap
Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud
theravet@newcap.eu
+33 (0)1 44 71 94 94

Press Relations
Arthur Rouillé / Ambre Delval
theravet@newcap.eu
+33 (0)1 44 71 00 15

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting